{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T10:55:22Z","timestamp":1697280922145},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T00:00:00Z","timestamp":1249430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00277-009-0797-4","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T12:33:31Z","timestamp":1249389211000},"page":"135-140","source":"Crossref","is-referenced-by-count":6,"title":["Long-term response to deferiprone therapy in Asian Indians"],"prefix":"10.1007","volume":"89","author":[{"given":"Inusha","family":"Panigrahi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram K.","family":"Marwaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi R.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita","family":"Trehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,5]]},"reference":[{"issue":"3","key":"797_CR1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","volume":"89","author":"NF Olivieri","year":"1997","unstructured":"Olivieri NF, Brittenham GM (1997) Iron-chelating therapy and the treatment of thalassemia. Blood 89(3):739\u2013755","journal-title":"Blood"},{"issue":"1","key":"797_CR2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2003-09-3167","volume":"104","author":"MJ Cunningham","year":"2004","unstructured":"Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR (2004) Complications of \u03b2-thalassemia major in North America. Blood 104(1):34\u201339","journal-title":"Blood"},{"key":"797_CR3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1196\/annals.1345.017","volume":"1054","author":"RC Hider","year":"2005","unstructured":"Hider RC, Zhou T (2005) The design of orally active iron chelators. Ann N Y Acad Sci 1054:141\u2013154","journal-title":"Ann N Y Acad Sci"},{"key":"797_CR4","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2005","unstructured":"Cappellini MD, Cohen A, Piga A et al (2005) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with {beta}-thalassemia. Blood 107:3455\u20133462","journal-title":"Blood"},{"key":"797_CR5","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-07-2933","volume":"107","author":"C Borgna-Pignatti","year":"2005","unstructured":"Borgna-Pignatti C, Cappellini MD, De Stefano P et al (2005) Cardiac morbidity and mortality in deferoxamine or deferiprone-treated patients with thalassemia major. Blood 107:3733\u20133737","journal-title":"Blood"},{"key":"797_CR6","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","volume":"107","author":"DJ Pennell","year":"2005","unstructured":"Pennell DJ, Berdoukas V, Karagiorga M et al (2005) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738\u20133744","journal-title":"Blood"},{"key":"797_CR7","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","volume":"361","author":"E Nisbet-Brown","year":"2003","unstructured":"Nisbet-Brown E, Olivieri NF, Giardina PJ et al (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose escalation trial. Lancet 361:1597\u20131602","journal-title":"Lancet"},{"key":"797_CR8","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","volume":"102","author":"AR Cohen","year":"2003","unstructured":"Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102:1583\u20131587","journal-title":"Blood"},{"key":"797_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","volume":"102","author":"AV Hoffbrand","year":"2003","unstructured":"Hoffbrand AV, Cohen A, Hershko C (2003) Role of deferiprone in chelation therapy for transfusional iron overload. Blood 102:17\u201324","journal-title":"Blood"},{"key":"797_CR10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","volume":"118","author":"A Ceci","year":"2002","unstructured":"Ceci A, Baiardi P, Felisi M et al (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 118:330\u2013336","journal-title":"Br J Haematol"},{"issue":"3","key":"797_CR11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.1998.00725.x","volume":"101","author":"P Tondury","year":"1998","unstructured":"Tondury P, Zimmermann A, Nielsen P, Hirt A (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 101(3):413\u2013415","journal-title":"Br J Haematol"},{"key":"797_CR12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2141.1995.tb05274.x","volume":"91","author":"FN Al-Refaie","year":"1995","unstructured":"Al-Refaie FN, Hershko C, Hoffbrand AV et al (1995) Results of long-term deferiprone (L1) therapy: a report by the international study group on oral iron chelators. Br J Haematol 91:224\u2013229","journal-title":"Br J Haematol"},{"key":"797_CR13","unstructured":"Olivieri NF, Brittenham GM (1997) Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO)[abstract]. Blood (suppl 90):1161a"},{"key":"797_CR14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","volume":"82","author":"MB Agarwal","year":"1992","unstructured":"Agarwal MB, Gupte SS, Viswanathan C et al (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassemia: Indian trial. Br J Haematol 82:460\u2013466","journal-title":"Br J Haematol"},{"key":"797_CR15","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199504063321404","volume":"332","author":"NF Olivieri","year":"1995","unstructured":"Olivieri NF, Brittenham GM, Matsui D et al (1995) Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 332:918\u2013922","journal-title":"N Engl J Med"},{"issue":"suppl.","key":"797_CR16","first-page":"1012","volume":"84","author":"C Hershko","year":"1994","unstructured":"Hershko C, Hoffbrand AV, Kosaryan M et al (1994) Results of long-term deferiprone (L1) therapy. A report by the international study group on oral iron chelators [abstract]. Blood 84(suppl.):1012","journal-title":"Blood"},{"issue":"suppl.","key":"797_CR17","first-page":"1436","volume":"84","author":"NF Olivieri","year":"1994","unstructured":"Olivieri NF, Sher GD, McKinnon JA et al (1994) The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1 [abstract]. Blood 84(suppl.):1436","journal-title":"Blood"},{"issue":"7","key":"797_CR18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","volume":"339","author":"NF Olivieri","year":"1998","unstructured":"Olivieri NF, Brittenham GM, McLaren CM et al (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339(7):417\u2013423","journal-title":"N Engl J Med"},{"key":"797_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","volume":"91","author":"AV Hoffbrand","year":"1998","unstructured":"Hoffbrand AV, Al-Refaie F, Davis B et al (1998) Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 91:295\u2013300","journal-title":"Blood"},{"issue":"4","key":"797_CR20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4038\/cmj.v47i4.3413","volume":"47","author":"GN Lucas","year":"2002","unstructured":"Lucas GN, Perera BJ, Fonseka EA et al (2002) Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Med J 47(4):119\u2013121","journal-title":"Ceylon Med J"},{"key":"797_CR21","first-page":"489","volume":"88","author":"A Piga","year":"2003","unstructured":"Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489\u2013496","journal-title":"Haematologica"},{"issue":"4","key":"797_CR22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000081268","volume":"112","author":"A Taher","year":"2004","unstructured":"Taher A, Aoun E, Sharara AI et al (2004) Five-year trial of deferiprone chelation therapy in thalassaemia major patients. Acta Haematol 112(4):179\u2013183","journal-title":"Acta Haematol"},{"issue":"4","key":"797_CR23","first-page":"12","volume":"17","author":"M Ayyub","year":"2005","unstructured":"Ayyub M, Ali W, Anwar M et al (2005) Efficacy and adverse-effects of oral iron chelator deferiprone (l1, 1, 2-dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassemia major in Pakistan. J Ayub Med Coll Abbottabad 17(4):12\u201315","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"2","key":"797_CR24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1179\/102453308X315924","volume":"13","author":"H Goel","year":"2008","unstructured":"Goel H, Girisha KM, Phadke SR (2008) Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. Hematology 13(2):77\u201382","journal-title":"Hematology"},{"key":"797_CR25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0140-6736(94)92585-2","volume":"343","author":"M Berkovitch","year":"1994","unstructured":"Berkovitch M, Laxer RM, Inman R et al (1994) Arthropathy in thalassemia patients receiving deferiprone. Lancet 343:1471\u20131472","journal-title":"Lancet"},{"key":"797_CR26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","volume":"108","author":"AR Cohen","year":"2000","unstructured":"Cohen AR, Galanello R, Piga A et al (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 108:305\u2013312","journal-title":"Br J Haematol"},{"key":"797_CR27","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1600-0609.1994.tb01323.x","volume":"53","author":"FN Al-Refaie","year":"1994","unstructured":"Al-Refaie FN, Wonke B, Hoffbrand AV (1994) Deferiprone associated myelotoxicity. Eur J Haematol 53:298\u2013301","journal-title":"Eur J Haematol"},{"key":"797_CR28","first-page":"1","volume":"33","author":"AV Hoffbrandt","year":"1996","unstructured":"Hoffbrandt AV (1996) Oral iron chelation. Semin Hematol 33:1\u20138","journal-title":"Semin Hematol"},{"key":"797_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000203854","volume":"95","author":"NF Olivieri","year":"1996","unstructured":"Olivieri NF (1996) Long-term therapy with deferiprone. Acta Haematologica 95:37\u201348","journal-title":"Acta Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0797-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-009-0797-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0797-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:12:48Z","timestamp":1590037968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0797-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0797-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,5]]}}}